RESUMEN
Quality registries are potential tools for improving health care documentation, but the quality and completeness of each registry should be ensured. This study aimed to evaluate the completion rate (completeness) and accuracy of data, first contact-to-registration time (timeliness), and case coverage of the Tampere Wound Registry (TWR) to assess whether it can be reliably used in clinical practice and for research purposes. Data from all 923 patients registered in the TWR between 5 June 2018 and 31 December 2020 were included in the analysis of data completeness, while data accuracy, timeliness and case coverage were analysed in those registered during the year 2020. In all analyses values over 80% were considered good and values over 90% excellent. The study showed that the overall completeness of the TWR was 81% and overall accuracy was 93%. Timeliness achieved 86% within the first 24 h, and case coverage was found to be 91%. When completion of seven selected variables was compared between TWR and patient medical records, the TWR was found to be more complete in five out of seven variables. In conclusion, the TWR proved to be a reliable tool for health care documentation and an even more reliable data source than patient medical records.
Asunto(s)
Enfermedades de la Piel , Úlcera , Humanos , Sistema de Registros , Exactitud de los Datos , Factores de Tiempo , DocumentaciónRESUMEN
Chronic ulcers cause a significant burden to patients and society. This study evaluated long-term mortality among patients with chronic ulcers diagnosed at a dermatology clinic between 1980 and 2010. The mortality risk and causes of death of 3,489 patients with ulcers were compared with a matched reference group of 10,399 individuals, and factors associated with increased mortality risk were examined. Long-term mortality was increased in patients with chronic ulcers (hazard ratio (HR) 1.74) and in both males and females (HR 1.99 and 1.62, respectively). Diabetes was the most relevant underlying cause of death (HR 8.98), and of the immediate causes of death, sepsis was strongly associated with mortality (HR 5.86). The mortality risk was highest among those with arterial ulcers (HR 2.85), but also increased in patients with atypical, mixed and venous leg ulcers. In conclusion, patients with chronic ulcers are at an increased mortality risk irrespective of age, sex and ulcer aetiology.
Asunto(s)
Diabetes Mellitus , Úlcera de la Pierna , Úlcera Varicosa , Femenino , Humanos , Masculino , Úlcera , Cicatrización de HeridasRESUMEN
Dermatitis herpetiformis (DH) is a common extraintestinal manifestation of coeliac disease presenting with itchy papules and vesicles on the elbows, knees, and buttocks. Overt gastrointestinal symptoms are rare. Diagnosis of DH is easily confirmed by immunofluorescence biopsy showing pathognomonic granular immunoglobulin A (IgA) deposits in the papillary dermis. A valid hypothesis for the immunopathogenesis of DH is that it starts from latent or manifest coeliac disease in the gut and evolves into an immune complex deposition of high avidity IgA epidermal transglutaminase (TG3) antibodies, together with the TG3 enzyme, in the papillary dermis. The mean age at DH diagnosis has increased significantly in recent decades and presently is 40â»50 years. The DH to coeliac disease prevalence ratio is 1:8 in Finland and the United Kingdom (U.K.). The annual DH incidence rate, currently 2.7 per 100,000 in Finland and 0.8 per 100,000 in the U.K., is decreasing, whereas the reverse is true for coeliac disease. The long-term prognosis of DH patients on a gluten-free diet is excellent, with the mortality rate being even lower than for the general population.
Asunto(s)
Enfermedad Celíaca/complicaciones , Enfermedad Celíaca/diagnóstico , Dermatitis Herpetiforme/diagnóstico , Dermatitis Herpetiforme/etiología , Biopsia , Enfermedad Celíaca/dietoterapia , Dermatitis Herpetiforme/dietoterapia , Dieta Sin Gluten , Epidermis/enzimología , Finlandia , Técnica del Anticuerpo Fluorescente , Tracto Gastrointestinal/metabolismo , Humanos , Inmunoglobulina A/metabolismo , Incidencia , Prevalencia , Transglutaminasas/metabolismo , Reino UnidoRESUMEN
GOALS: We analyzed from our prospectively collected series of patients with dermatitis herpetiformis (DH) whether small-bowel histologic findings are changing and how serum tissue transglutaminase (TG2) IgA antibodies correlate to mucosal damage. BACKGROUND: DH is an extraintestinal manifestation of celiac disease presenting with itchy blistering rash and pathognomonic IgA deposits in the skin. Prominent gastrointestinal symptoms are rare, and small-bowel findings range from severe villous atrophy (SVA) and partial villous atrophy (PVA) to normal mucosa with inflammatory changes. METHODS: The cohort included 393 patients (214 male and 179 female) with DH having small-bowel biopsies performed at Tampere University Hospital since 1970. The small-bowel findings were calculated in the three 15-year periods, and in the last period they were correlated with serum IgA class TG2 antibody levels measured by enzyme-linked immunosorbent assay. RESULTS: The prevalence of SVA decreased significantly (P=0.032), from 42% in the first study period to 29% in the last study period. A concomitant increase was seen in PVA, from 33% to 41%, and normal villous architecture, from 25% to 30%. The patients with SVA (P<0.001) and PVA (P=0.046) had significantly higher TG2 antibody levels than those with normal villous architecture. CONCLUSIONS: This long-term study in patients with DH disclosed a significant decrease in the occurrence of SVA. Serum IgA TG2 antibody levels correlated to damage in the small bowel. The trend toward milder small-bowel histology in DH suggests that a similar pattern could occur in the pool of undiagnosed celiac disease from which DH develops.
Asunto(s)
Dermatitis Herpetiforme/epidemiología , Mucosa Intestinal/patología , Intestino Delgado/patología , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Atrofia , Autoanticuerpos/sangre , Estudios de Cohortes , Dermatitis Herpetiforme/sangre , Dermatitis Herpetiforme/patología , Dieta Sin Gluten , Femenino , Finlandia/epidemiología , Proteínas de Unión al GTP/inmunología , Humanos , Incidencia , Masculino , Persona de Mediana Edad , Prevalencia , Proteína Glutamina Gamma Glutamiltransferasa 2 , Índice de Severidad de la Enfermedad , Transglutaminasas/inmunología , Adulto JovenRESUMEN
Dermatitis herpetiformis (DH) is an itchy blistering skin disease with predilection sites on elbows, knees, and buttocks. Diagnosis is confirmed by showing granular immunoglobulin A deposits in perilesional skin. DH is one manifestation of coeliac disease; the skin symptoms heal with gluten free diet (GFD) and relapse on gluten challenge. Of the first-degree relatives, 5% may be affected by either condition. Tissue transglutaminase (TG2) is the autoantigen in coeliac disease and epidermal transglutaminase (TG3) in DH. Both diseases conditions exhibit TG2-specific autoantibodies in serum and small bowel mucosa; patients with DH have IgA-TG3 in the skin. There are some divergencies between these two phenotypes. One-fourth of DH patients do not have small bowel mucosal villous atrophy, but virtually all have coeliac-type inflammatory changes. The skin symptoms respond slowly to GFD. The incidence of coeliac disease is increasing, whereas the opposite is true for DH. A female predominance is evident in coeliac disease, while DH may be more common in males. Coeliac disease carries the risk of small intestinal T-cell lymphoma; in DH B-cell lymphomas at any site may prevail. Adult coeliac disease carries a slightly increased elevated mortality risk, whereas in DH, the relative mortality rate is significantly decreased. Key messages Dermatitis herpetiformis is a cutaneous manifestation of coeliac disease; both conditions are genetically determined and gluten-dependent. Gastrointestinal symptoms and the degree of villous atrophy are less obvious in dermatitis herpetiformis than in coeliac disease. Both show tissue transglutaminase (TG2) specific autoantibodies in serum and small bowel mucosa. In addition, TG3-targeted IgA antibodies are found in the skin of DH patients Both conditions carry an increased elevated risk of lymphoma, in coeliac disease small intestinal T-cell lymphoma, in dermatitis herpetiformis mainly B-cell lymphoma at various sites. Coeliac disease is currently eight times more common that DH; the incidence of DH is decreasing in contrast to that of coeliac disease, where it is increasing.
Asunto(s)
Enfermedad Celíaca/diagnóstico , Dermatitis Herpetiforme/diagnóstico , Dermatitis Herpetiforme/inmunología , Piel/patología , Adulto , Autoanticuerpos/sangre , Autoantígenos/inmunología , Enfermedad Celíaca/epidemiología , Enfermedad Celíaca/inmunología , Dermatitis Herpetiforme/dietoterapia , Dermatitis Herpetiforme/patología , Dieta Sin Gluten , Linfoma de Células T Asociado a Enteropatía/complicaciones , Femenino , Proteínas de Unión al GTP/sangre , Humanos , Inmunoglobulina A/aislamiento & purificación , Inmunoglobulina A/metabolismo , Incidencia , Mucosa Intestinal/inmunología , Mucosa Intestinal/patología , Intestino Delgado/inmunología , Intestino Delgado/patología , Linfoma de Células B/complicaciones , Masculino , Persona de Mediana Edad , Proteína Glutamina Gamma Glutamiltransferasa 2 , Riesgo , Piel/inmunología , Transglutaminasas/sangreRESUMEN
BACKGROUND: Transglutaminase (TG)2 is the autoantigen in celiac disease, but also TG3 antibodies have been detected in the serum of celiac disease patients. AIMS: To investigate the correlations between serum TG3 antibodies and clinical and histological manifestations of celiac disease and to assess gluten-dependency of TG3 antibodies. METHODS: Correlations between serum TG3 antibody levels measured from 119 adults and children with untreated coeliac disease and the demographic data, clinical symptoms, celiac antibodies, histological data and results of laboratory tests and bone mineral densities were tested. TG3 antibodies were reinvestigated in 97 celiac disease patients after 12 months on a gluten-free diet (GFD). RESULTS: TG3 antibody titers were shown to correlate with the age at celiac disease diagnosis. Further, negative correlation with TG3 antibodies and intestinal γδ+ cells at diagnosis and on GFD was detected. Correlations were not detected with the clinical manifestation of celiac disease, TG2 or endomysial autoantibodies, laboratory values, severity of mucosal villous atrophy, associated diseases or complications. TG3 antibody titers decreased on GFD in 56% of the TG3 antibody positive patients. CONCLUSION: Serum TG3 antibody positivity in celiac disease increases as the diagnostic age rises. TG3 antibodies did not show similar gluten-dependency as TG2 antibodies.
Asunto(s)
Factores de Edad , Autoanticuerpos/sangre , Enfermedad Celíaca/sangre , Inmunoglobulina A/sangre , Transglutaminasas/inmunología , Adolescente , Adulto , Anciano , Autoantígenos/inmunología , Niño , Preescolar , Dermatitis Herpetiforme/sangre , Dieta Sin Gluten , Femenino , Finlandia , Humanos , Mucosa Intestinal/patología , Masculino , Persona de Mediana Edad , Adulto JovenRESUMEN
Dermatitis herpetiformis (DH) is a blistering skin disease, which is regarded as an extra-intestinal manifestation of coeliac disease. Refractory cases of coeliac disease, that do not respond to a gluten-free diet and which carry an increased risk of lymphoma, are well-known in coeliac disease. To determine whether refractory cases of DH with active rash and persistent small bowel atrophy occur we analysed our series of 403 patients with DH. Seven (1.7%) patients, who had been on a gluten-free diet for a mean of 16 years, but who still required dapsone to treat the symptoms of DH, were identified. Of these, one patient died from mucinous adenocarcinoma before re-examination. At re-examination skin immunoglobulin A (IgA) deposits were found in 5/6 refractory and 3/16 control DH patients with good dietary response. Small bowel mucosa was studied at re-examination from 5 refractory and 8 control DH patients and was normal in all 5 refractory and 7/8 control DH patients. One refractory DH patient died from adenocarcinoma, but no lymphoma developed in any of the patients. This study documents for the first time refractory DH, in which the rash is non-responsive to a gluten-free diet, but the small bowel mucosa heals. This differs from refractory coeliac disease, in which the small bowel mucosa does not heal on a gluten-free diet.
Asunto(s)
Enfermedad Celíaca/dietoterapia , Dapsona/uso terapéutico , Dermatitis Herpetiforme/terapia , Dieta Sin Gluten , Piel/efectos de los fármacos , Adolescente , Adulto , Atrofia , Biopsia , Enfermedad Celíaca/diagnóstico , Enfermedad Celíaca/inmunología , Niño , Dermatitis Herpetiforme/diagnóstico , Dermatitis Herpetiforme/dietoterapia , Dermatitis Herpetiforme/inmunología , Femenino , Humanos , Mucosa Intestinal/inmunología , Mucosa Intestinal/patología , Intestino Delgado/inmunología , Intestino Delgado/patología , Masculino , Persona de Mediana Edad , Estudios Retrospectivos , Piel/inmunología , Piel/patología , Factores de Tiempo , Resultado del Tratamiento , Cicatrización de Heridas , Adulto JovenRESUMEN
Dermatitis herpetiformis (DH) is an itchy, blistering skin disease with sites of predilection at the elbows, knees and buttocks. Although DH is mostly asymptomatic, all patients exhibit small bowel villous atrophy or at least coeliac-type inflammatory changes. Deposition of immunoglobulin A (IgA) in the papillary dermis is a key diagnostic feature of DH. Epidermal transglutaminase (TG3) is the antigen for IgA deposited in the skin, and tissue transglutaminase (TG2) is the antigen for IgA deposited in the small bowel mucosa. Clinically silent, but immunologically active coeliac disease in the gut appears to result in IgA TG3 antibody complexes aggregated into DH skin. The prevalence of DH in northern Europe is high (30-75/100,000), but its incidence is decreasing, possibly due to increased recognition of subclinical coeliac disease. The rash and small bowel heal on a gluten-free diet, which is a life-long treatment. The risk of non-Hodgkin's lymphoma is increased, but in patients with DH who adhere strictly to a gluten-free diet long-term prognosis is excellent.
Asunto(s)
Dermatitis Herpetiforme/dietoterapia , Dermatitis Herpetiforme/inmunología , Dieta Sin Gluten , Inmunoglobulina A/metabolismo , Transglutaminasas/inmunología , Enfermedad Celíaca/dietoterapia , Enfermedad Celíaca/inmunología , Pruebas Enzimáticas Clínicas , Dermatitis Herpetiforme/diagnóstico , Proteínas de Unión al GTP/inmunología , Humanos , Mucosa Intestinal/inmunología , Intestino Delgado/inmunología , Proteína Glutamina Gamma Glutamiltransferasa 2RESUMEN
OBJECTIVE: Dermatitis herpetiformis (DH) is a cutaneous form of celiac disease affecting â¼ 17% of celiac disease patients. The aim was to determine how often celiac disease precedes the development of DH, and what is the impact of gluten-free diet (GFD) in this phenotype change. MATERIAL AND METHODS: Our prospectively collected DH series from 1970 comprised 514 patients. We analyzed all DH patients who at least 2 years earlier had been diagnosed with celiac disease. DH diagnosis was confirmed by showing immunoglobulin A deposits in dermis. Serological and small bowel mucosal findings were analyzed, and the strictness of GFD treatment before and after the diagnosis of DH was evaluated. RESULTS: Twenty (4%) DH patients had a prior diagnosis of celiac disease. The median time interval between celiac disease and DH detection was 9.5 years. Before DH appeared 4 patients had been on a normal gluten-containing diet, 10 had dietary lapses on a GFD, and 6 were on a strict GFD. Celiac autoantibodies were positive in 7 out of 19 patients, and 5 out of 7 undergoing small bowel biopsy had partial villous atrophy. Following DH diagnosis the rash was controlled after a median of 6 months on a strict GFD. CONCLUSIONS: Patients with celiac disease may develop DH by time. This is most often an indicator of poor adherence to GFD, and a rigorous dietary intervention is necessary. In the majority of cases, DH will be detected without prior celiac disease diagnosis, but the physicians should recognize this phenotype alteration.
Asunto(s)
Enfermedad Celíaca/dietoterapia , Dermatitis Herpetiforme/dietoterapia , Dieta Sin Gluten , Mucosa Intestinal/patología , Fenotipo , Adolescente , Adulto , Anciano , Atrofia , Autoanticuerpos/sangre , Enfermedad Celíaca/complicaciones , Enfermedad Celíaca/patología , Niño , Preescolar , Dermatitis Herpetiforme/sangre , Dermatitis Herpetiforme/complicaciones , Femenino , Humanos , Lactante , Masculino , Persona de Mediana Edad , Cooperación del Paciente , Factores de Tiempo , Adulto JovenRESUMEN
Dermatitis herpetiformis (DH) is an extraintestinal manifestation of coeliac disease. Untreated coeliac disease patients are known to have transglutaminase 2 (TG2)-targeted IgA deposits in the small bowel mucosa. To evaluate whether similar intestinal IgA deposits are also present in DH and whether the deposits disappear with gluten-free diet, 47 untreated and 27 treated DH patients were studied. Seventy-nine percent of untreated and 41% of the treated DH patients had TG2-specific IgA deposits in the small bowel, and the presence of the deposits showed a significant association with the degree of small bowel villous atrophy (p < 0.001). Other coeliac-disease related inflammatory markers were also investigated, and the density of small bowel mucosal intraepithelial γδ(+) T cells was increased in 91% of untreated and 73% of treated DH patients. The results show that the majority of untreated DH patients have similar gluten-dependent TG2-specific IgA deposits the small bowel mucosa as coeliac disease patients.
Asunto(s)
Autoanticuerpos/análisis , Enfermedad Celíaca/inmunología , Dermatitis Herpetiforme/inmunología , Inmunoglobulina A/análisis , Mucosa Intestinal/inmunología , Intestino Delgado/inmunología , Transglutaminasas/inmunología , Adolescente , Adulto , Anciano , Atrofia , Autoinmunidad , Biomarcadores/análisis , Enfermedad Celíaca/complicaciones , Enfermedad Celíaca/diagnóstico , Enfermedad Celíaca/dietoterapia , Enfermedad Celíaca/enzimología , Dermatitis Herpetiforme/diagnóstico , Dermatitis Herpetiforme/enzimología , Dieta Sin Gluten , Femenino , Proteínas de Unión al GTP , Humanos , Mucosa Intestinal/enzimología , Mucosa Intestinal/patología , Intestino Delgado/enzimología , Intestino Delgado/patología , Masculino , Persona de Mediana Edad , Proteína Glutamina Gamma Glutamiltransferasa 2 , Resultado del Tratamiento , Adulto JovenRESUMEN
BACKGROUND AND OBJECTIVE: Previous small studies suggest that chronic atrophic gastritis is common in dermatitis herpetiformis (DH). We here examined the frequency and topography of chronic gastritis in 93 untreated DH subjects and in 186 controls with dyspepsia. METHODS: Specimens were drawn from the gastric corpus and antrum and examined for atrophy, intestinal metaplasia, and Helicobacter pylori. Duodenal biopsies were taken. RESULTS: Atrophic corpus gastritis was more frequent in DH than in controls (16.0% and 2.7%, resp., P < 0.001); atrophy in the antrum was rare in both groups (3.2% and 1.1%, P = 0.34). Intestinal metaplasia was present in 13 (14.0%) DH and 12 (6.5%) control patients (P = 0.038) and H. pylori in 17 (18.3%) and 17 (9.3%) (P = 0.028), respectively. Small-bowel villous atrophy was seen in 76% of the DH patients, equally in patients with and without chronic gastritis. One DH patient with atrophic gastritis developed gastric cancer. CONCLUSION: In DH, chronic atrophic gastritis was common in the corpus, but not in the antrum. H. pylori will partly explain this, but corpus atrophy is suggestive of an autoimmune etiology. Atrophic gastritis may increase the risk of gastric cancer. We advocate performing upper endoscopy with sufficient histologic samples in DH.